GENPF.US Genix Pharmaceuticals Corporation

Healthcare Pharmaceuticals USA Stocks
0.0104 USD
Close of Nov 14, 2026
0.0104 0.0357
Market cap
USD 637K
P/E
-
P/B
1.57x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Apr 2026.

Is GENPF.US undervalued?

Graham number

The Graham number of Genix Pharmaceuticals Corporation cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Genix Pharmaceuticals Corporation fundamental analysis

No fundamental analysis for Genix Pharmaceuticals Corporation yet.

Genix Pharmaceuticals Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Genix Pharmaceuticals Corporation

Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with a focus on nutraceuticals and pharmaceuticals in Canada. The company offers generic ophthalmic prescription products, ophthalmic nutraceutical formulations, and prescription generic drugs; ophthalmic OTC products; and eye ointments and drops. It also provides Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Rechlor, …

Full company profile